



RESEARCH

Open Access

# Activation of GABA<sub>B</sub> receptors inhibits protein kinase B /Glycogen Synthase Kinase 3 signaling

Frances Fangjia Lu<sup>1†</sup>, Ping Su<sup>1†</sup>, Fang Liu<sup>1,2\*</sup> and Zafiris J Daskalakis<sup>1,2\*</sup>

## Abstract

Accumulated evidence has suggested that potentiation of cortical GABAergic inhibitory neurotransmission may be a key mechanism in the treatment of schizophrenia. However, the downstream molecular mechanisms related to GABA potentiation remain unexplored. Recent studies have suggested that dopamine D2 receptor antagonists, which are used in the clinical treatment of schizophrenia, modulate protein kinase B (Akt)/glycogen synthase kinase (GSK)-3 signaling. Here we report that activation of GABA<sub>B</sub> receptors significantly inhibits Akt/GSK-3 signaling in a  $\beta$ -arrestin-dependent pathway. Agonist stimulation of GABA<sub>B</sub> receptors enhances the phosphorylation of Akt (Thr-308) and enhances the phosphorylation of GSK-3 $\alpha$  (Ser-21)/ $\beta$  (Ser-9) in both HEK-293T cells expressing GABA<sub>B</sub> receptors and rat hippocampal slices. Furthermore, knocking down the expression of  $\beta$ -arrestin2 using siRNA abolishes the GABA<sub>B</sub> receptor-mediated modulation of GSK-3 signaling. Our data may help to identify potentially novel targets through which GABA<sub>B</sub> receptor agents may exert therapeutic effects in the treatment of schizophrenia.

## Introduction

Schizophrenia (SCZ) is a debilitating disorder that exacts enormous personal, social and economic costs. Accumulated evidence has suggested that potentiation of cortical GABAergic inhibitory neurotransmission may be a novel treatment target for resistant SCZ. The human GABA<sub>B</sub> receptor gene has been localized to regions in the genome associated with schizophrenia, 6p21.3 [1,2]. In addition, the expression of the GABA<sub>B</sub> receptor has been shown to be reduced in the human schizophrenic brain [3]. As well, the GABA<sub>B</sub> receptor agonist, baclofen has been reported to have some efficacy in SCZ patients [4]. Baclofen was also shown to improve cognition in an animal model of methamphetamine-induced psychosis [5] and elicit antipsychotic-like effects in the rat paradigm of prepulse inhibition of the startle response, an animal phenotype for modeling SCZ [6].

Transcranial magnetic stimulation (TMS) indices of GABA<sub>B</sub> receptor mediated inhibitory neurotransmission can be altered through antipsychotic treatment. The

cortical silent period (CSP) represents a TMS neurophysiological index of GABA<sub>B</sub> receptor mediated inhibitory neurotransmission whereas short interval cortical inhibition (SICI) represents a TMS neurophysiological index of GABA<sub>A</sub> receptor mediated inhibitory neurotransmission. Both the CSP and SICI were lowered in patients with SCZ [7,8]. Clozapine treated patients demonstrated significantly longer CSP durations of large effect (i.e., Cohen's  $D > 3$ ) but no change in SICI relative to unmedicated SCZ patients and healthy subjects [9]. These findings suggest that clozapine potentiates the GABA<sub>B</sub> receptor and also underscores the possibility that the GABA<sub>B</sub> receptor may play a key role in the treatment of SCZ. Furthermore, a recent in-vivo study by Wu et al. also confirmed these findings [10] which reported that the binding of the GABA<sub>B</sub> receptor antagonist [<sup>3</sup>H]-CGP54626A increased when treated with clozapine. There was a significant correlation between the clozapine dose and the increase of [<sup>3</sup>H]-CGP54626A binding in linear regression analysis. In the presence of clozapine, a left shift was shown for specific [<sup>3</sup>H]-CGP54626A binding in competition with different concentrations of GABA. Clozapine also increased [<sup>3</sup>H]-CGP54626A binding at GABA<sub>B</sub> R1 subunit when HEK293 cells overexpressed GABA<sub>B</sub> receptors, highlighting a potential therapeutic target for clozapine.

\* Correspondence: f.liu.a@utoronto.ca; Jeff.Daskalakis@camh.ca

†Equal contributors

<sup>1</sup>Centre for Addiction and Mental Health, 250 College Street, Toronto, ON M5T 1, Canada

<sup>2</sup>Departments of Psychiatry, University of Toronto, Toronto, ON M5T 1R8, Canada

GSK-3 is a protein kinase originally identified and named for its ability to phosphorylate and inactivate the metabolic enzyme glycogen synthase [11]. Subsequently, GSK-3 was found to be broadly involved in neural systems and modulate many aspects of neuronal function, including gene expression, neurogenesis, synaptic plasticity, neuronal structure, and neuronal death and survival [12-14]. Accumulating evidence implicates abnormal activity of GSK-3 in psychiatric disorders, such as bipolar disorder, depression, schizophrenia, ADHD and Alzheimer's Disease [15-17] and GSK-3 is a potential protein kinase target for antipsychotics. Atypical antipsychotics, such as clozapine and olanzapine, can regulate phosphoserine-GSK-3 and inhibit its activity [18].

There are two highly homologous GSK-3 enzymes, GSK-3 $\alpha$  and GSK-3 $\beta$ , derived from separate genes. Both GSK-3 $\alpha$  and GSK-3 $\beta$  are expressed throughout the brain [19] and they are regulated by several mechanisms. The most well-defined regulatory mechanism is by phosphorylation of serine-9 in GSK-3 $\beta$  or serine-21 in GSK-3 $\alpha$ , which inhibits GSK-3 activity [20-22]. The Akt signaling pathway often is a major regulator of GSK-3 because Akt phosphorylates GSK-3 on these inhibitory serine residues, which has been shown to be involved in dopamine signaling and many aspects of psychiatric disorders [23]. Conversely, enzymatic activity is enhanced by phosphorylation of tyrosine-216 in GSK-3 $\beta$  and tyrosine-279 in GSK-3 $\alpha$ , which are autophosphorylation sites, and can facilitate substrate binding to GSK-3, although the mechanism of this modification are not well-defined [24].

The fact that all current antipsychotic drugs exert their effect through the blockade of dopamine D2 receptors (D2R) has established that increased D2R signaling is an important part of the pathophysiology of schizophrenia [25,26]. Recent studies have suggested that D2R can activate the Akt/GSK-3 pathway via G protein-independent signaling [20,27]. D2R-mediated Akt/GSK-3 regulation involves the recruitment of  $\beta$ -arrestin2 to the D2R and specific dephosphorylation/inactivation of the serine/threonine kinase Akt on its regulatory Thr-308 residue but not the second regulatory residue (Ser-473) [20]. Phosphorylation of Akt in response to DA leads to a reduction of kinase activity and a concomitant activation of its substrates GSK-3 $\alpha$  (Ser-21)/ $\beta$  (Ser-9) [20]. More importantly, antipsychotics including haloperidol, clozapine and olanzapine strongly decrease recruitment of  $\beta$ -arrestin2 to D2R [18,28,29]. These data support a critical role of D2R-mediated GSK-3 signaling in the pathology of schizophrenia and suggest that antipsychotics exert their therapeutic effect by targeting GSK-3 signaling. Therefore, we investigated whether activation of GABA<sub>B</sub> receptors can modulate GSK-3 signaling. This will be a step towards establishing the relationship between the GABA<sub>B</sub> receptor and downstream targets of

antipsychotic action, and potentially identifying new therapeutic targets for schizophrenia.

## Materials and methods

### Material

The cDNAs encoding human GABA<sub>B</sub>R1a and GABA<sub>B</sub>R2 subunits in pcDNA3 were kindly supplied by Dr. O. Carter Snead in The Hospital for Sick Children in Toronto.

The  $\beta$ -arrestin2 siRNA targeting human  $\beta$ -arrestin2 were purchased from Santa Cruz Biotechnology (cat# sc-29208).

### Cell culture and transient transfection

HEK293T cells were cultured in  $\alpha$ -MEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen) and maintained in incubators at 37°C, 5% CO<sub>2</sub>. HEK293T cells were grown to 90% confluence before being transiently transfected with plasmid constructs and/or siRNA using X-treme GENE 9 DNA transfection reagents (Roche). About 24–48 hours after transfection, cells were used for experiments.

### Protein extracts isolation

Transfected HEK293T cells were collected, washed with 1  $\times$  PBS, and solubilized with the buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 2 mM EDTA, 1 mM PMSE, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 4 mM NaF, 20 mM  $\beta$ -glycerophosphate and 5  $\mu$ l/ml protease inhibitor cocktail (Sigma) and centrifuged at 10,000 g at 4°C for 10 min. The concentration of supernatant was qualified with a BCA protein assay. Finally, the samples were boiled with SDS sample buffer for 5 min, and subjected to SDS-PAGE for Western blot analysis.

### Gel Electrophoresis and western blotting

Samples were separated by SDS-PAGE with 5% stacking gel and 10% separating gel and transferred to a nitrocellulose membrane. After blocking for 1 hour with 5% fat-free milk powder in TBST (10 mM Tris-HCl, 150 mM NaCl, 0.05% Tween-20, pH 7.4), blots were incubated overnight at 4 °C with primary antibodies: 1:1,000 anti-phosphorylated GSK-3 $\alpha$ / $\beta$  (Ser-21/ 9) (Cell Signaling Technology), 1:1,000 anti-GSK-3 $\alpha$  (Cell Signaling Technology), 1:1,000 anti-GSK-3 $\beta$  (Cell Signaling Technology), 1:200 anti- $\beta$ -arrestin2 (Santa Cruz Biotechnology), 1:10,000 anti- $\alpha$ -tubulin (Sigma), 1:1000 anti-GSK-3 $\alpha$ / $\beta$  (Y-279/Y-216) (Millipore), 1:1000 anti-Akt (Abcam), 1:1000 anti-phosphorylated-Akt (Thr-308) (Cell Signaling Technology), and 1:1000 anti-phosphorylated-Akt (Ser-473) (Abcam). After washes, blots were incubated with HRP-conjugated secondary antibodies (Sigma) for 2 hours at room temperature. Immunoactivity was visualized with ECL Western blot detection reagents (GE Healthcare). Data representative of three experimental replicates are shown.

### Statistical analysis


All values are shown as means  $\pm$  SEM. For comparisons between two groups, t-tests were performed. For comparisons of more than two groups, one-way or two-way ANOVA followed by the Student-Newman-Keuls post hoc analysis was performed.

### Results

#### Activation of GABA<sub>B</sub> receptors increases phosphorylated GSK-3 $\alpha/\beta$ at Ser-21/Ser-9 sites

Previous studies have suggested that phosphorylation of GSK-3 $\alpha/\beta$  at Ser-21/Ser-9 sites significantly decreases


active site availability, thus inhibiting GSK-3 activity [30]. To investigate whether GABA<sub>B</sub> receptors are involved in the GSK-3 signaling, we initially tested whether activation of GABA<sub>B</sub> receptors can modulate the phosphorylation of GSK-3 $\alpha/\beta$  at Ser-21/Ser-9 sites in HEK293T cells expressing GABA<sub>B</sub>R1a and GABA<sub>B</sub>R2 subunits. As shown in Figure 1A, SKF97541 (1  $\mu$ M, 30 min), a specific GABA<sub>B</sub> receptor agonist significantly increased GSK-3 $\alpha/\beta$  (Ser-21/Ser-9) phosphorylation, an effect that can be blocked by the GABA<sub>B</sub> receptor-specific antagonist CGP52432 (10  $\mu$ M, 30 min). Interestingly, CGP52432 alone induced a small but



**Figure 1** Activation of GABA<sub>B</sub> receptors elevates GSK-3 $\alpha/\beta$  phosphorylation at Ser21/Ser 9 sites, but has no effect on phosphorylation of GSK-3 $\alpha/\beta$  at Y279/Y216 sites in HEK293T cells expressing GABA<sub>B</sub> receptors. **A.** Western blot analysis of phosphorylated GSK-3 $\alpha/\beta$  (Ser-21/Ser-9) levels in extract prepared from HEK293T cells transfected with GABA<sub>B</sub> receptor in the presence of GABA<sub>B</sub> receptor antagonist and/or agonist. GSK- $\alpha/\beta$  was used as a loading control. **B.** Densitometric analysis of phosphorylated GSK-3 $\alpha/\beta$  (Ser-21/Ser-9). The intensity of phospho-GSK-3 $\alpha/\beta$  was quantified by densitometry (software: Image J, NIH). **C.** Western blot analysis of phosphorylated GSK-3 $\alpha/\beta$  (Y-279/Y-216) levels in extract prepared from HEK293T cells transfected with GABA<sub>B</sub> receptor in the presence of GABA<sub>B</sub> receptor antagonist and/or agonist. GSK-3 $\alpha/\beta$  was used as a loading control. **D.** Densitometric analysis of phosphorylated GSK-3 $\alpha/\beta$  (Y-279/Y-216). The intensity of phospho-GSK-3 $\alpha/\beta$  was quantified by densitometry (software: Image J, NIH). Data were analyzed by one-way ANOVA (\* $P < 0.05$ , \*\* $P < 0.01$ ,  $n = 3$ ).

significant decrease in GSK-3 $\alpha/\beta$  (Ser-21/Ser-9) phosphorylation, suggesting that GABA<sub>B</sub> receptors may have constitutive activity that is consistent with previous reports [31]. The total expression of GSK 3 $\alpha/\beta$  is not altered among all four groups. The intensity of

each protein expression was quantified using densitometry (Figure 1B). These data suggest that activation of GABA<sub>B</sub> receptors may enhance GSK-3 $\alpha/\beta$  (Ser-21/Ser-9) phosphorylation, leading to reduced GSK-3 activity.



**Figure 2** Activation of GABA<sub>B</sub> receptors elevates Akt (Thr-308) phosphorylation in HEK293T cells expressing GABA<sub>B</sub> receptors, which can be blocked with pretreatment of PI3K inhibitor Wortmannin. **A.** Western blot analysis of phosphorylated Akt (Thr-308) or Akt (Ser-473) levels in extract prepared from HEK 293T cells transfected with GABA<sub>B</sub> receptor in the presence of GABA<sub>B</sub> receptor antagonist and/or agonist. Akt was used as a loading control. **B-C.** Densitometric analysis of phosphorylated Akt (Thr-308) (B) and Akt (Ser-473) (C). The intensity of phospho-Akt was quantified by densitometry (software: Image J, NIH). **D.** Western blot analysis of phosphorylated GSK-3 $\alpha/\beta$  (Ser-21/Ser-9) or GSK-3 $\alpha/\beta$  levels in extract prepared from HEK293T cells transfected with GABA<sub>B</sub> receptor pretreated with/without Wortmannin (100 nM, 24 h) in the presence or absence of GABA<sub>B</sub> receptor agonist SKF97541. **E.** Densitometric analysis of phosphorylated GSK-3 $\alpha/\beta$  (Ser-21/Ser-9). The intensity of phospho-GSK-3 $\alpha/\beta$  (Ser-21/Ser-9) was quantified by densitometry (software: Image J, NIH). Data were analyzed by one-way or two-way ANOVA (\* $P < 0.05$ , \*\* $P < 0.01$ ,  $n = 3$ ).

### **Activation of GABA<sub>B</sub> receptors has no effect on phosphorylated GSK-3 $\alpha$ / $\beta$ at Y-279/Y-216 sites**

Previous studies have suggested that phosphorylation at the tyrosine-216 site of GSK-3 $\beta$  or tyrosine-279 of GSK-3 $\alpha$  enhances the enzymatic activity of GSK-3. We have shown that activation of GABA<sub>B</sub> receptors may inhibit GSK-3 activity by enhancing GSK-3 $\alpha$ / $\beta$  (Ser-21/Ser-9) phosphorylation. We then tested whether activation of GABA<sub>B</sub> receptors can inhibit GSK-3 activity by inhibiting GSK-3 $\alpha$ / $\beta$  phosphorylation at the Y-279/Y-216 sites of GSK-3 $\alpha$ / $\beta$ . As shown in Figure 1C-D, activation of GABA<sub>B</sub> receptors has no effect on GSK-3 $\alpha$ / $\beta$  (Y-279/Y-216) phosphorylation. These data suggest that GABA<sub>B</sub> receptors may modulate GSK-3 activity by selectively phosphorylating GSK-3 $\alpha$ / $\beta$  at the Ser-21/Ser-9 sites.

### **Activation of GABA<sub>B</sub> receptors significantly enhances Akt phosphorylation at Thr-308**

Previous studies have shown that GSK-3 $\alpha$ / $\beta$  activity can be negatively regulated by Akt, a serine/threonine kinase. Dephosphorylation of Akt on its regulatory Thr-308 site leads to a reduction of Akt kinase activity that induces the activation of its substrate GSK-3 [32]. Since we have observed enhanced GSK-3 $\alpha$ / $\beta$  (Ser-21/Ser-9) phosphorylation upon activation of GABA<sub>B</sub> receptors, we hypothesized that Akt phosphorylation may also be modulated by the activation of GABA<sub>B</sub> receptors. As shown in Figure 2A-C, GABA<sub>B</sub> receptor stimulation significantly enhances Akt phosphorylation at Thr-308, but not at Ser-473. These data are consistent with previous studies on dopamine D2 receptor activation of GSK-3 signaling although the direction of effect is opposite.

To further confirm the requirement of Akt activation in the GABA<sub>B</sub> receptor-mediated GSK-3 signaling, we tested whether phosphatidylinositol 3-kinases (PI3K) inhibitor can block the GABA<sub>B</sub> receptor-mediated GSK-3 phosphorylation as previous studies have shown blockade of PI3K inhibits Akt activity [33]. As shown in Figure 2D-E, wortmannin (100 nM, 24 h), a PI3K inhibitor, block the effect of GABA<sub>B</sub> receptor on the phosphorylation of GSK3 at Ser21/Ser9 sites, further confirming the requirement of Akt in the GABA<sub>B</sub> receptor-mediated GSK-3 signaling.

### **GABA<sub>B</sub> receptors modulate GSK-3 $\alpha$ / $\beta$ phosphorylation through a Gi-protein-independent/ $\beta$ -arrestin2-dependent pathway**

Both GABA<sub>B</sub> and dopamine D2 receptors are Gi/o-coupled receptors. Traditionally, G-protein coupled receptors exert their effects only via G-protein mediated signaling. However, recent studies have suggested that dopamine D2 receptors can activate the Akt/GSK-3 pathway via G-protein independent/ $\beta$ -arrestin2-dependent signaling [20,27]. Thus, we tested whether Gi/o protein and

$\beta$ -arrestin2 are involved in the GABA<sub>B</sub> receptor-mediated modulation of GSK-3 signaling. As shown in Figure 3A-B, pre-incubating the cells expressing GABA<sub>B</sub> receptor or primary cultured hippocampal neurons (Figure 4C-D) with pertussis toxin (PTX) (200 ng/ml, 14–18 h), which uncouples the receptors from Gi/o protein, has no effect on GABA<sub>B</sub> receptor-mediated modulation of the phosphorylation of GSK-3 $\alpha$ / $\beta$  (Ser-21/Ser-9). This result suggests that GABA<sub>B</sub> receptors modulate phosphorylation of GSK-3 $\alpha$ / $\beta$  through a Gi-protein-independent pathway.


We then confirmed the efficiency of  $\beta$ -arrestin2 siRNA for knocking-down the expression of  $\beta$ -arrestin2. As shown in Figure 3C, the expression of  $\beta$ -arrestin2 in HEK-293T cells is significantly decreased when transfected with  $\beta$ -arrestin2 siRNA (Santa Cruz Biotechnology), compared to cells transfected with control siRNA. We then measured the phosphorylation of GSK-3 $\alpha$ / $\beta$  (Ser-21/Ser-9) in HEK-293T cells transfected with GABA<sub>B</sub> receptors and  $\beta$ -arrestin2 siRNA or control siRNA. As shown in Figure 3D-E, activation of GABA<sub>B</sub> receptors significantly enhanced the phosphorylation of GSK-3 $\alpha$ / $\beta$  (Ser-21/Ser-9) in HEK-293T cells transfected with GABA<sub>B</sub> receptors and control siRNA, while activation of GABA<sub>B</sub> receptors failed to alter the phosphorylation of GSK-3 $\alpha$ / $\beta$  (Ser-21/Ser-9) in HEK-293T cells transfected with GABA<sub>B</sub> receptors and  $\beta$ -arrestin2 siRNA. These data indicate that  $\beta$ -arrestin2 is required for GABA<sub>B</sub> receptor-mediated modulation of GSK-3 signaling.

### **Activation of GABA<sub>B</sub> receptors increases phosphorylated GSK-3 $\alpha$ / $\beta$ at Ser-21/Ser-9 sites in rat hippocampal slices**

To examine the effect of GABA<sub>B</sub> receptor on GSK-3 signaling in a relevant cellular milieu, rat hippocampal slices were utilized in parallel experiments. As shown in Figure 4A-B, pre-treatment of the hippocampal slices with the GABA<sub>B</sub> receptor specific agonist SKF97541 significantly enhanced the phosphorylation of GSK-3 $\alpha$ / $\beta$  (Ser-21/Ser-9). Consistent with the data obtained in HEK-293T cells transfected with GABA<sub>B</sub> receptors, GABA<sub>B</sub> receptor antagonist CGP52432 abolished the GABA<sub>B</sub> receptor effect on phosphorylation of GSK-3 $\alpha$ / $\beta$  (Ser-21/Ser-9). These data further confirm that GABA<sub>B</sub> receptors are involved in GSK-3 signaling.

## **Discussion**


Our findings suggest that activation of GABA<sub>B</sub> inhibits GSK-3 signaling through a  $\beta$ -arrestin2-dependent pathway (Figure 5). This pathway involves the upregulation of Akt phosphorylation at Thr-308 and GSK-3 $\alpha$ / $\beta$  phosphorylation at Ser-21/Ser-9. As a G-protein coupled receptor (GPCR), the GABA<sub>B</sub> receptor was thought to exert its effects via coupling to pertussis toxin (PTX) sensitive Gi/o proteins, that in turn regulate voltage-gated Ca<sup>2+</sup> (Ca<sub>v</sub>) or



**Figure 3 Effect of GABA<sub>B</sub> receptors on GSK-3α/β phosphorylation is a Gi protein-independent/β-arrestin2-dependent pathway in HEK293T cells expressing GABA<sub>B</sub> receptors.** **A.** Western blot analysis of phosphorylated GSK-3α/β (Ser-21/Ser-9) levels in extract prepared from HEK293T cells transfected with GABA<sub>B</sub> receptors in the presence or absence of GABA<sub>B</sub> receptor agonist with/without PTX (200 ng/ml, 14–18 h). GSK-3α/β was used as a loading control. **B.** Densitometric analysis of phosphorylated GSK-3α/β (Ser-21/Ser-9). **C.** Western blot analysis of efficacy of β-arrestin2 siRNA on β-arrestin2 express in HEK293T cells. **D.** Western blot analysis of phosphorylated GSK-3α/β (Ser-21/Ser-9) levels in extract prepared from HEK293T cells transfected with GABA<sub>B</sub> receptors and β-arrestin2 siRNA or control siRNA in the presence or absence of GABA<sub>B</sub> receptor agonist. GSK-3α/β was used as a loading control. **E.** Densitometric analysis of phosphorylated GSK-3α/β (Ser-21/Ser-9). The intensity of phospho-GSK-3α/β was quantified by densitometry (software: Image J, NIH). Data were analyzed by two-way ANOVA (\**P* < 0.05, \*\**P* < 0.01, *n* = 3).

G protein-gated inwardly rectifying K<sup>+</sup> (GIRK) channels, and inhibit adenylyl cyclase. However, our results suggest that activation of GABA<sub>B</sub> receptor modulates GSK-3 signaling in a G-protein independent manner, as PTX failed to block the GABA<sub>B</sub> receptor effect on GSK-3α/β

phosphorylation. Interestingly, previous studies have shown that activation of dopamine D2 receptors, which are also Gi/o coupled GPCRs, similarly modulate GSK-3 signaling in a β-arrestin dependent pathway. However, the D2 receptor effect on GSK-3 is opposite to the GABA<sub>B</sub>




**Figure 4** Activation of GABA<sub>B</sub> receptors elevates GSK-3 $\alpha/\beta$  phosphorylation in rat hippocampal slices, and this effect can not be blocked by PTX when pretreating primary cultured hippocampal neurons. **A.** Western blot analysis of phosphorylated GSK-3 $\alpha/\beta$  (Ser-21/Ser-9) levels in extract prepared from rat hippocampal slices in the presence of GABA<sub>B</sub> receptor agonist and/or antagonist. GSK-3 $\alpha/\beta$  was used as a loading control. **B.** Densitometric analysis of phosphorylated GSK-3 $\alpha/\beta$  (Ser-21/Ser-9). **C.** Western blot analysis of phosphorylated GSK-3 $\alpha/\beta$  (Ser-21/Ser-9) levels in extract prepared from rat primary cultured hippocampal neurons pretreated with PTX (200 ng/ml, 14–18 h) in the presence or absence of GABA<sub>B</sub> receptor agonist SKF97541. GSK-3 $\alpha/\beta$  was used as a loading control. **D.** Densitometric analysis of phosphorylated GSK-3 $\alpha/\beta$  (Ser-21/Ser-9). The intensity of phospho-GSK-3 $\alpha/\beta$  was quantified by densitometry (software: Image J, NIH). Data were analyzed by one-way or two-way ANOVA (\* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ,  $n = 3$ ).

receptor effect. Activation of D2 receptors leads to  $\beta$ -arrestin2 recruitment to the D2 receptors and formation of a  $\beta$ -arrestin2-scaffolded protein complex that includes protein phosphatase 2A (PP2A), Akt and GSK-3 $\alpha/\beta$ . PP2A dephosphorylates Akt at Thr-308 which subsequent activation of GSK-3 $\alpha/\beta$  as a consequence of dephosphorylation of GSK-3 at Ser-9 and 21 [34]. It is worth noting that both receptors modulate GSK-3 signaling by changing the Akt phosphorylation at Thr-308 site and GSK 3 $\alpha/\beta$  phosphorylation at Ser-21/Ser-9 sites. The fact that both GABA<sub>B</sub> receptor agonists and D2 receptor antagonists exert antipsychotic effects [5,35], together with previous findings that antipsychotics are potent antagonists of the

dopamine-induced recruitment of  $\beta$ -arrestin2 to the D2 receptors [36], suggests that inhibition of GSK-3 activity may be a molecular mechanism through which GABA<sub>B</sub> receptor agonists have antipsychotic effects.

Previous studies have suggested that GPCRs can signal without an external chemical trigger, i.e., in a constitutive or spontaneous manner [36]. For example, dopamine D5 receptors enhance cAMP accumulation without agonist stimulation [38,39]. Consistent with this idea, GABA<sub>B</sub> receptors also display constitutive activity as we observed a significant decrease of GSK-3 $\alpha/\beta$  phosphorylation at Ser-21/Ser-9 sites treated only with the GABA<sub>B</sub> receptor antagonist CGP52432. The general

### Schematic Model of GABA<sub>B</sub>R-mediated GSK-3 pathway



**Figure 5** Schematic model of GABA<sub>B</sub> receptor mediated GSK-3 signaling. Activation of GABA<sub>B</sub> receptors enhances the phosphorylation of Akt and GSK-3 $\alpha/\beta$ , which inactivates GSK-3 signaling. Activation of D2 receptors has the opposite effect as previously reported [37].

physiological purpose of such basal activity may be to permit bi-direction control of receptor activity. With constitutively active pathways, the output can be either increased or decreased from a mid-range level.

GSK-3 is a multi-functional serine/threonine kinase. Its activity is regulated negatively by the phosphorylation of Ser-9 and positively by the phosphorylation of Tyr-216, a GSK-3 $\beta$  auto-phosphorylation site required for regulating its activity. Previous studies have shown that GSK-3 $\beta$  phosphorylation at Tyr-216 can be prevented by its interaction with DISC1 (Disrupted-in-schizophrenia-1 protein) [40]. Thus, it is possible that GABA<sub>B</sub> receptors inhibit GSK-3 activity through direct inhibition of GSK-3 $\beta$  phosphorylation at Tyr-216 site. However, our results indicate that activation of GABA<sub>B</sub> receptors has no effect on GSK-3 $\beta$  phosphorylation at Tyr-216. Interestingly, this data is also consistent with the dopamine D2 receptor effect on GSK-3 phosphorylation as activation of D2 receptor also has no effect on GSK-3 $\beta$  phosphorylation at Tyr-216.

Available evidence suggests that antipsychotic drugs exert their antipsychotic effects in schizophrenia through the blockade of dopamine D2 receptors (D2R) or D2R in combination with the serotonin receptor 2A (5-HT<sub>2A</sub>R) [25,26,41]. GABA<sub>B</sub> receptors and D2R belong to the super family of G-protein coupled receptors (GPCRs) that exert their biological effects via intracellular G protein-coupled signaling cascades [42-45]. D2Rs display a complex pattern of signal transduction via their coupling to the Gi/Go protein. Previously, D2Rs were known to stimulate a number of signal transduction pathways including the inhibition of adenylate cyclase activity, PI

(phosphatidylinositol) turnover, potentiation of arachidonic acid release, inwardly rectifying K<sup>+</sup> and Ca<sup>2+</sup> channels and mitogen activated protein kinases [43]. Recently several studies have suggested that D2R can activate the Akt/GSK-3 pathway via  $\beta$ -arrestin2-dependent signaling. D2R-mediated Akt/GSK-3 regulation involves the recruitment of  $\beta$ -arrestin2 to the D2R and the formation of signaling complexes containing  $\beta$ -arrestin2, protein phosphatase 2A (PP2A) and Akt. Formation of this protein complex leads to specific dephosphorylation/inactivation of the serine/threonine kinase Akt on its regulatory Thr-308 residue but not the second regulatory Ser-473 residue [23,27,43] the inactivation of Akt, in response to DA stimulation, leads to a reduction of kinase activity and a concomitant activation of its substrates GSK-3 $\alpha$  (Ser-21)/ $\beta$  (Ser-9) since both are negatively regulated by Akt [20]. Interestingly, D2R-mediated modulation of GSK-3 signaling targets the same phosphorylation sites as GABA<sub>B</sub> receptors, but the functional effects are the opposite. The fact that antipsychotics block D2R and also antagonize the agonist-induced recruitment of  $\beta$ -arrestin2 to D2R [29], supports our contention that GABA<sub>B</sub> receptor-mediated inhibition of GSK-3 signaling may be a target for the development of novel antipsychotic medications.

#### Competing interests

The authors declare that they have no competing interests.

#### Authors' contributions

FLL carried out all the Western Blot analysis. PS carried out all the cell transfection, data analysis and prepared all the figures. FL and ZJD supervised the project and wrote the manuscript. All authors read and approve the manuscript.



Received: 31 October 2012 Accepted: 24 November 2012  
Published: 28 November 2012

## References

- Goei VL, Choi J, Ahn J, Bowls CL, Raha-Chowdhury R, Gruen JR: **Human gamma-aminobutyric acid B receptor gene: complementary DNA cloning, expression, chromosomal location, and genomic organization.** *Biol Psychiatry* 1998, **44**:659–666.
- Grifa A, Totaro A, Rommens JM, Carella M, Roetto A, Borgato L, Zelante L, Gasparini P: **GABA (gamma-amino-butyric acid) neurotransmission: identification and fine mapping of the human GABAB receptor gene.** *Biochem Biophys Res Commun* 1998, **250**:240–245.
- Mizukami K, Ishikawa M, Hidaka S, Iwakiri M, Sasaki M, Iritani S: **Immunohistochemical localization of GABAB receptor in the entorhinal cortex and inferior temporal cortex of schizophrenic brain.** *Prog Neuropsychopharmacol Biol Psychiatry* 2002, **26**:393–396.
- Frederiksen PK: **Letter: Baclofen in the treatment of schizophrenia.** *Lancet* 1975, **1**:702.
- Arai S, Takuma K, Mizoguchi H, Ibi D, Nagai T, Kamei H, Kim HC, Yamada K: **GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice.** *Eur J Pharmacol* 2009, **602**:101–104.
- Bortolato M, Frau R, Orru M, Piras AP, Fa M, Tuberi A, Puligheddu M, Gessa GL, Castellani MP, Mereu G, Marrosu F: **Activation of GABA(B) receptors reverses spontaneous gating deficits in juvenile DBA/2J mice.** *Psychopharmacology (Berl)* 2007, **194**:361–369.
- Wobrock T, Schneider M, Kadovic D, Schneider-Axmann T, Ecker UK, Retz W, Rosler M, Falkai P: **Reduced cortical inhibition in first-episode schizophrenia.** *Schizophr Res* 2008, **105**:252–261.
- Daskalakis ZJ, Christensen BK, Chen R, Fitzgerald PB, Zipursky RB, Kapur S: **Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation.** *Arch Gen Psychiatry* 2002, **59**:347–354.
- Shi-Kai L, Paul BF, Mellisa D, Chen R, Daskalakis ZJ: **The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia.** *Biol Psychiatry* 2009, **85**:503–509.
- Wu Y, Blichowski M, Daskalakis ZJ, Wu Z, Liu CC, Cortez MA, Snead OC 3rd: **Evidence that clozapine directly interacts on the GABAB receptor.** *Neuroreport* 2011, **22**:37–41.
- Embi N, Rylatt DB, Cohen P: **Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase.** *Eur J Biochem* 1980, **107**:519–527.
- Doble BW, Woodgett JR: **GSK-3: tricks of the trade for a multi-tasking kinase.** *J Cell Sci* 2003, **116**:1175–1186.
- Frame S, Cohen P: **GSK3 takes centre stage more than 20 years after its discovery.** *Biochem J* 2001, **359**:1–16.
- Jope RS, Johnson GV: **The glamour and gloom of glycogen synthase kinase-3.** *Trends Biochem Sci* 2004, **29**:95–102.
- Klein PS, Melton DA: **A molecular mechanism for the effect of lithium on development.** *Proc Natl Acad Sci USA* 1996, **93**:8455–8459.
- Medina M, Avila J: **Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.** *Curr Pharm Des* 2010, **16**:2790–2798.
- Amar S, Belmaker RH, Agam G: **The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases.** *Curr Pharm Des* 2011, **17**:2264–2277.
- Li X, Rosborough KM, Friedman AB, Zhu W, Roth KA: **Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics.** *Int J Neuropsychopharmacol* 2007, **10**:7–19.
- Yao HB, Shaw PC, Wong CC, Wan DC: **Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain.** *J Chem Neuroanat* 2002, **23**:291–297.
- Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, Caron MG: **Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade.** *Proc Natl Acad Sci USA* 2004, **101**:5099–5104.
- Chalecka-Franaszek E, Chuang DM: **Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons.** *Proc Natl Acad Sci USA* 1999, **96**:8745–8750.
- De Sarno P, Li X, Jope RS: **Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium.** *Neuropharmacology* 2002, **43**:1158–1164.
- Beaulieu JM, Marion S, Rodriguez RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR, Caron MG: **A beta-arrestin 2 signaling complex mediates lithium action on behavior.** *Cell* 2008, **132**:125–136.
- Beurel E, Jope RS: **The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways.** *Prog Neurobiol* 2006, **79**:173–189.
- Seeman P: **Targeting the dopamine D2 receptor in schizophrenia.** *Expert Opin Ther Targets* 2006, **10**:515–531.
- Seeman P, Lee T: **Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons.** *Science* 1975, **188**:1217–1219.
- Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG: **An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior.** *Cell* 2005, **122**:261–273.
- Alimohamad H, Rajakumar N, Seah YH, Rushlow W: **Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum.** *Biol Psychiatry* 2005, **57**:533–542.
- Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, Gainetdinov RR, Caron MG: **Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.** *Proc Natl Acad Sci USA* 2008, **105**:13656–13661.
- Russell JC, Kishimoto K, O'Driscoll C, Hossain MA: **Neuronal pentraxin 1 induction in hypoxic-ischemic neuronal death is regulated via a glycogen synthase kinase-3alpha/beta dependent mechanism.** *Cell Signal* 2011, **23**:673–682.
- Gjoni T, Urwyler S: **Changes in the properties of allosteric and orthosteric GABAB receptor ligands after a continuous, desensitizing agonist pretreatment.** *Eur J Pharmacol* 2009, **603**:37–41.
- Bongers G, Sallmen T, Passani MB, Mariottini C, Wendelin D, Lozada A, Marle A, Navis M, Blandina P, Bakker RA, Panula P, Leurs R: **The Akt/GSK-3beta axis as a new signaling pathway of the histamine H(3) receptor.** *J Neurochem* 2007, **103**:248–258.
- Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, Fini M, McCubrey JA: **Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.** *Oncotarget* 2012, **3**(4):371–394.
- Campa VM, Kypka RM: **Issues associated with the use of phosphospecific antibodies to localize active and inactive pools of GSK-3 in cells.** *Biol Direct* 2011, **6**:4.
- Arai S, Takuma K, Mizoguchi H, Ibi D, Nagai T, Takahashi K, Kamei H, Nabeshima T, Yamada K: **Involvement of pallidotegmental neurons in methamphetamine- and MK-801-induced impairment of prepulse inhibition of the acoustic startle reflex in mice: reversal by GABAB receptor agonist baclofen.** *Neuropsychopharmacology* 2008, **33**:3164–3175.
- Smit MJ, Vischer HF, Bakker RA, Jongejan A, Timmerman H, Pardo L, Leurs R: **Pharmacogenomic and structural analysis of constitutive G protein-coupled receptor activity.** *Annu Rev Pharmacol Toxicol* 2007, **47**:53–87.
- Beaulieu J-M, Gainetdinov RR, Caron MG: **The Akt-GSK-3 signaling cascade in the actions of dopamine.** *Trends Pharmacol Sci* 2007, **28**(4):166–172.
- Demchishyn LL, McConkey F, Niznik HB: **Dopamine D5 receptor agonist high affinity and constitutive activity profile conferred by carboxyl-terminal tail sequence.** *J Biol Chem* 2000, **275**:23446–23455.
- Plouffe B, D'Aouast JP, Laquerre V, Liang B, Tiberi M: **Probing the constitutive activity among dopamine D1 and D5 receptors and their mutants.** *Methods Enzymol* 2010, **484**:295–328.
- Mao Y, Ge X, Frank CL, Madison JM, Koehler AN, Doud MK, Tassa C, Berry EM, Soda T, Singh KK, Biechele T, Petryshen TL, Moon RT, Haggarty SJ, Tsai LH: **Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling.** *Cell* 2009, **136**:1017–1031.
- Tyson PJ, Roberts KH, Mortimer AM: **Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors?** *Int J Neurosci* 2004, **114**:593–611.
- Missale C, Nash SR, Robinson SW, Jaber M, Caron MG: **Dopamine receptors: from structure to function.** *Physiol Rev* 1998, **78**:189–225.

43. Strange PG: **Studies on the structure and function of D2-dopamine receptors.** *Biochem Soc Trans* 1992, **20**:126–130.
44. Vallone D, Picetti R, Borrelli E: **Structure and function of dopamine receptors.** *Neurosci Biobehav Rev* 2000, **24**:125–132.
45. Pinard A, Seddik R, Bettler B: **GABAB receptors: physiological functions and mechanisms of diversity.** *Adv Pharmacol* 2010, **58**:231–255.

doi:10.1186/1756-6606-5-41

**Cite this article as:** Lu et al.: Activation of GABA<sub>B</sub> receptors inhibits protein kinase B /Glycogen Synthase Kinase 3 signaling. *Molecular Brain* 2012 5:41.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

